2010 Fiscal Year Final Research Report
Analysis of resistance mechanism of cell death in chemotherapy and monoclonal antibody therapy
| Project/Area Number |
17016077
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | Japanese Foundation For Cancer Research |
|---|
Principal Investigator |
HATAKE Kitohiko Japanese Foundation For Cancer Research, 癌化学療法センター臨床部, 部長 (80192699)
|
|---|
| Project Period (FY) |
2005 – 2010
|
| Keywords | 化学療法 / 抗体療法 / 耐性 / 細胞死 |
|---|
| Research Abstract |
I studied basic research in drug resistance mechanism as well as clinical samples analysis. Imatinib resistance, partly is explained by ABL mutation and autophagy pathway will be a next target. Rituximab resistance in CD20+ lymphoma is explained partly by CD20 mutation. I established bortezomib-resistant myeloma cell line.
We also established the assay system for ADCC and CDC.
|
